Janssen Pharmaceutical’s DARZALEX FASPRO gains FDA approval for AL amyloidosis treatment

Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), marking a major milestone in the treatment ... Read More